Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.43 |
| ▸ | NOS2 | P35228 | 5/20 | 0.41 |
| ▸ | NOS3 | P29474 | 4/20 | 0.41 |
| ▸ | NOS1 | P29475 | 4/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL21827041 | 1.00 | OTC (0.46) | OTCSMN1; SMN2DDAH1NOS2NOS3 | |
| Arginine SCHEMBL30193366 | 1.00 | OTC (0.46) | OTCSMN1; SMN2DDAH1NOS2NOS3 | |
| Arginine SCHEMBL423591 | 1.00 | OTC (0.46) | OTCSMN1; SMN2DDAH1NOS2NOS3 | |
| Arginine SCHEMBL150229 | 0.89 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27530824 | 0.89 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL27692295 | 0.89 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL248897 | 0.89 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Arginine SCHEMBL150228 | 0.89 | OTC (0.49) | OTCDDAH1NOS2NOS3NOS1 | |
| Malic Acid SCHEMBL11164058 | 0.89 | SMN1; SMN2 (0.40) | OTCSMN1; SMN2DDAH1NOS2NOS3 | |
| L-Citrulline SCHEMBL319676 | 0.88 | OTC (0.48) | OTCSMN1; SMN2DDAH1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119606781-A | Application of amino acid group assembly, reagent and cosmetic composition thereof, and preparation method and application of amino acid group assembly | 常州市智态生创科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-3525775-B1 | ARGININE AND ITS USE AS A T CELL MODULATOR | INST RES BIOMEDICINE (CH) | 2023-06-07 | — | — | EP | claimed |
| US-20210353705-A1 | METHOD AND COMPOSITION FOR RELIEVING FATIGUE AND RESTORING ENERGY | INDIA GLOBALIZATION CAPITAL, INC. (US) | 2021-11-18 | — | — | US | claimed |
| US-11167015-B2 | Arginine and its use as a T cell modulator | INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) | 2021-11-09 | — | — | US | claimed |
| CN-109382756-B | Chemical mechanical polishing method for tungsten | 罗门哈斯电子材料CMP控股股份有限公司 | 2021-07-30 | — | — | CN | claimed |
| WO-2020072997-A1 | METHOD AND COMPOSITION FOR RELIEVING FATIGUE AND RESTORING ENERGY | INDIA GLOBALIZATION CAPITAL, INC. (US) | 2020-04-09 | — | — | WO | claimed |
| US-10600655-B2 | Chemical mechanical polishing method for tungsten | ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, INC. (US) | 2020-03-24 | — | — | US | claimed |
| US-20190307856-A1 | Arginine And Its Use As A T Cell Modulator | INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) | 2019-10-10 | — | — | US | claimed |
| EP-3525775-A1 | ARGININE AND ITS USE AS A T CELL MODULATOR | Institute for Research in Biomedicine (CH) | 2019-08-21 | — | — | EP | claimed |
| WO-2018069471-A1 | ARGININE AND ITS USE AS A T CELL MODULATOR | INSTITUTE FOR RESEARCH IN BIOMEDICINE (CH) | 2018-04-19 | — | — | WO | claimed |
| EP-2322165-A1 | Apo2 ligand/TRAIL formulations | Genentech, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-7842668-B1 | Apo-2 ligand/trail formulations | GENENTECH, INC. (US) | 2010-11-30 | — | — | US | claimed |
| EP-1450847-B1 | APO2 ligand/ TRAIL formulations and uses thereof | GENENTECH INC (US) | 2010-09-29 | — | — | EP | claimed |
| US-7741282-B2 | ApO2 ligand/TRAIL formulations | GENENTECH, INC. (US) | 2010-06-22 | — | — | US | claimed |
| EP-1450847-A4 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH INC (US) | 2007-08-29 | — | — | EP | claimed |
| JP-2005521640-A | — | — | 2005-07-21 | — | — | JP | claimed |
| US-20050080006-A1 | Apo2 ligand/trail formulations | GENENTECH, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050020498-A1 | Apo-2 ligand/trail formulations | GENENTECH, INC. | 2005-01-27 | — | — | US | claimed |
| EP-1450847-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003042344-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2003-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11167015-B2 | Arginine and its use as a T cell modulator | CD4, NFATC1, PRMT1 | OTC 2300/4885SMN1; SMN2 4313/4885DDAH1 1057/4885 |
| US-20190307856-A1 | Arginine And Its Use As A T Cell Modulator | CD4, NFATC1, PRMT1 | OTC 2300/4885SMN1; SMN2 4313/4885DDAH1 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.